Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety as Potential Antimycobacterial Agents.

1 2 4-triazole Hydrazone antimycobacterial activity

Journal

Turkish journal of pharmaceutical sciences
ISSN: 2148-6247
Titre abrégé: Turk J Pharm Sci
Pays: Turkey
ID NLM: 101717890

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 26 04 2018
accepted: 04 08 2018
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 27 5 2020
Statut: ppublish

Résumé

The aim of this study was to synthesize, characterize, and screen some new 1-(4-((2-(4-substitutedphenyl)hydrazono)methyl)phenyl)-1H-1,2,4-triazole derivatives for their antimycobacterial activities. The target compounds The biological assay results showed that the methylsulfonyl-substituted derivative Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compounds was as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against

Identifiants

pubmed: 32454746
doi: 10.4274/tjps.galenos.2018.43660
pii: 21098
pmc: PMC7227891
doi:

Types de publication

Journal Article

Langues

eng

Pagination

432-436

Informations de copyright

©Copyright 2019 Turk J Pharm Sci, Published by Galenos Publishing House.

Déclaration de conflit d'intérêts

Conflict of Interest: No conflict of interest was declared by the authors.

Références

Clin Med (Lond). 2015 Dec;15 Suppl 6:s37-42
pubmed: 26634680
Ultrason Sonochem. 2003 Jul;10(4-5):265-70
pubmed: 12818392
Respir Med. 2006 Dec;100(12):2085-97
pubmed: 17113007
Antimicrob Agents Chemother. 1997 May;41(5):1004-9
pubmed: 9145860
Int J Antimicrob Agents. 2006 Dec;28(6):543-4
pubmed: 17101262
Org Lett. 2012 May 4;14(9):2402-5
pubmed: 22519727
Int J Tuberc Lung Dis. 2015 May;19(5):517-24
pubmed: 25868018
Ann Am Thorac Soc. 2015 May;12(5):674-9
pubmed: 25664920
Lancet Infect Dis. 2016 Apr;16(4):e34-46
pubmed: 27036358
Nat Rev Drug Discov. 2013 Mar;12(3):175-6
pubmed: 23449293
Bioorg Med Chem. 2002 Jul;10(7):2193-8
pubmed: 11983516
Adv Drug Deliv Rev. 2016 Jul 1;102:55-72
pubmed: 27151308
Int J Infect Dis. 2017 Mar;56:181-184
pubmed: 27818361
Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):255-60
pubmed: 16435570
Eur Respir J. 2013 Jun;41(6):1393-400
pubmed: 23018916
J Infect Public Health. 2014 Mar-Apr;7(2):75-91
pubmed: 24216518
Eur J Drug Metab Pharmacokinet. 2007 Oct-Dec;32(4):197-203
pubmed: 18348468
Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):103-8
pubmed: 11112090
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92
pubmed: 20442432
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3068-73
pubmed: 11248033
J Biol Chem. 2009 Sep 11;284(37):25211-9
pubmed: 19605350
J Enzyme Inhib Med Chem. 2009 Feb;24(1):117-24
pubmed: 18629678
Lancet. 2010 Jun 12;375(9731):2100-9
pubmed: 20488518

Auteurs

Keriman Özadali Sari (K)

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey.

Oya Ünsal Tan (O)

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey.

Dharmarajan Sriram (D)

Birla Institute of Technology and Science - Pilani, Pharmacy Group, Medicinal Chemistry and Antimycobacterial Research Laboratory, Hyderabad Campus, Jawahar Nagar, Hyderabad, Andhra Pradesh, India.

Ayla Balkan (A)

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey.

Classifications MeSH